Acquired Von Willebrand’s Syndrome in Systemic Lupus Erythematosus

Table 1

Laboratory data of patient.

	Initial	Final	Reference values
WBC	11.0/nL	7.8/nL	3.9–10.6/nL
Hb	4.6 g/dL	8.1 g/dL	13.5–17.5 g/dL
Hct	14.20%	25.80%	41–53%
Plt	112/	450/nL	150–440/nL
INR	1.06	1.00	0.9–1.2
aPTT	50.6 sec	43.7 sec	20.1–31.2 sec
Fibrinogen	308 mg/dL	NT	200–400 mg/dL
VWF : Ag	8%	10%	5–217%
VWF : RCo	0%	0%	50–150%
FVIII : C	2%	6%	60–150%
Cr	0.9 mg/dL	0.8 mg/dL	0.1–1.5 mg/dL
Albumin	1.1 g/dL	2.5 g/dL	3.5–5.5 g/dL
Protein/Cr ratio	2477 mg/g	NT	≤84 mg/g
ANA	1 : 320, homogeneous	NT	<1 : 80
Anti-dsDNA	344 IU/mL	NT	≤99 IU/mL
C3	<30 mg/dL	NT	90–180 mg/dL
C4	<6 mg/dL	NT	10–40 mg/dL
CRP	5.7 mg/L	NT	0–5.0 mg/L
ESR	100 mm/h	NT	0–15 mm/h
Reticulocytes	3.21%	NT	0.5–2%
LDH	290 U/L	NT	100–210 U/L
Haptoglobin	219 mg/dL	NT	43–212 mg/dL
Total bilirubin	0.1 mg/dL	NT	0.1–1.2 mg/dL
AST	19 U/L	NT	1–40 U/L
ALT	9 U/L	NT	1–40 U/L
ALP	49 U/L	NT	30–115 U/L
Direct Coombs test	Negative	NT	Negative
TSH	10.773 mIU/L	NT	0.47–6.90 mIU/L
Free T4	1.19 ng/dL	NT	0.74–2 ng/dL

WBC: white blood cell count; Hb: hemoglobin; Hct: hematocrit; Plt: platelet count; INR: international normalized ration; aPTT: activated partial thromboplastin time; VWF : Ag: von Willebrand factor antigen; VWF : RCo: von Willebrand factor ristocetin cofactor; FVIII : C: factor VIII procoagulant activity; Cr: creatinine; NT: not tested; ANA: antinuclear antibodies; anti-dsDNA: anti-double stranded DNA antibodies; C3: complement component 3; C4: complement component 4; CRP: C reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; TSH: thyroid stimulating hormone.
At last follow-up.
decreased to 86/nL on the 4th day of admission.